Latest News
Revolution Medicines, Inc.
- Revolution Medicines Q3FY26 Results: Earnings release set for Nov 4
- Revolution Medicines Begins Phase 3 RASolve 308 Trial of Zoldonrasib in RAS G12D Non-squamous NSCLC
- Enterprise value to EBITDA forward of Revolution Medicines, Inc. – BOATS:RVMDW
- EU Medicines Agency Recommends Revolution Medicines' Rasonque for Advanced Pancreatic Cancer
- EMA committee backs Revolution Medicines' Rasonque for metastatic pancreatic cancer
- Revolution Medicines' Europe efforts signal solo launch ambitions for cancer drug
- Revolution Medicines' Europe efforts signal solo launch ambitions for cancer drug
- Revolution Medicines Daraxonrasib: The Best Inventions of 2026
- Revolution Medicines wins EU committee backing for pancreatic cancer treatment
- Why is Revolution Medicines stock sliding today?
- Revolution Medicines CEO on Defeating the RAS Gene
- Form 4 Revolution Medicines Inc For: 24 September By Investing.com
Headlines from the last 30 days, linking to the original publishers. See all market news →